European equities traded in the US as American depositary receipts were higher late Friday morning, rising 1.55% to 1,293.05 on the S&P Europe Select ADR Index. The index is up more than 5% for the week.
From continental Europe, the gainers were led by biopharmaceutical companies Cellectis (CLLS) and argenx (ARGX), which advanced 14% and 5.6% respectively. They were followed by pharmaceutical company Novo Nordisk (NVO) and biopharmaceutical company Genfit (GNFT), which increased 4.6% and 2.5% respectively.
The decliners from continental Europe were led by biopharmaceutical company DBV Technologies (DBVT) and internet advertising firm Criteo (CRTO), which fell 4.3% and 4% respectively. They were followed by furniture manufacturer Natuzzi (NTZ), which dropped 3.5%.
From the UK and Ireland, the gainers were led by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and Amarin (AMRN), which climbed 8.3% and 6.4% respectively. They were followed by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company NuCana (NCNA), which rose 3.8% and 2.7% respectively.
The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Adaptimmune Therapeutics (ADAP), which lost 7% and 2.3% respectively. They were followed by software firm Endava (DAVA) and cruise line operator Carnival (CUK), which were down 2.1% each.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.